CancerCompass is dedicated to provided you with the most up to date cancer information and news. Visit our website to find all our articles on Other Cancer News http://www.cancercompass.com/other-cancer-news.htm Sat, 07 Nov 2009 00:00:00 GMT Sat, 07 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Mouth cancer (also called oral cancer) is a malignant growth which can occur in any part of the mouth including the lips and tongue. In the UK, the numbers of new cases have risen by over 41 per cent over the last ten years(1). About 5,325 people get cancer of the mouth each year and the disease kills one person every five hours. Treated in its early stages, mouth cancer is curable but if not detected early, it kills around one in two sufferers. http://www.cancercompass.com/cancer-news/article/32366.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Drugs used to treat psychiatric disorders are highly effective at killing cancer cells, opening up potential new lines of treatments. Dr Louise Lurze-Mann of the University of NSW School of Biotechnology and Biomolecular Sciences was talking with psychiatric researchers at the University of Queensland when they mentioned that people with diseases like schizophrenia appear to have low rates of cancer, despite being more inclined to smoke than the general population. http://www.cancercompass.com/cancer-news/article/32367.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Uterine serous carcinomas typically have a characteristic morphology (papillary architecture, high-grade nuclei) and immunoprofile (diffuse/strong p53 expression, loss of hormone receptor expression) that distinguish them from most endometrial endometrioid carcinomas. http://www.cancercompass.com/cancer-news/article/32361.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Results of two phase 1 studies demonstrate that the novel, investigational cancer vaccines MKC1106-MT and MKC1106-PP are well-tolerated and show encouraging immune response rates and objective tumor response in advanced melanoma, prostate cancer and other solid malignancies, setting the stage for phase 2 studies. The data are being presented at the International Society for Biological Therapy of Cancer 2009 Annual Meeting. http://www.cancercompass.com/cancer-news/article/32364.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT It's a safe bet to presume there are soup recipes in today's column because it's colder, furnaces are running and it just seems like a fall thing to do. http://www.cancercompass.com/cancer-news/article/32365.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT U.S. scientists say they have discovered a small molecule that inhibits the actions of a protein cancer cells require for survival. The researchers said they determined the molecule, called PES, inhibits a type of protein called a heat-shock protein that helps cells survive heat, lack of nutrients and other cell-damaging conditions. http://www.cancercompass.com/cancer-news/article/32368.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT We sought to improve outcomes for patients with high-risk head and neck squamous cell cancer (HNSCC) after surgical resection by testing the feasibility and safety of early postoperative chemotherapy followed by concurrent chemoradiotherapy. Eligible patients had resected, stages III to IV HNSCC with positive margins, extracapsular nodal extension, or multiple positive nodes, investigators in the United States report. http://www.cancercompass.com/cancer-news/article/32369.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Polo-like kinase 1 (Plk1) is becoming an increasingly attractive target for cancer management. Plk1 has been shown to be overexpressed in a variety of cancers; however its role in skin cancers is not well-understood, scientists in the United States report. http://www.cancercompass.com/cancer-news/article/32370.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT A recently discovered form of the protein that triggers blood clotting may play a key role in the molecular mechanisms leading to the growth of certain metastatic cancers, according to new research reported by an international team of scientists. http://www.cancercompass.com/cancer-news/article/32371.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT According to a study from the United States, Malignant gliomas are characterized by invasive and infiltrative behavior that generally involves the destruction of normal brain tissue. Strategies to treat infiltrating gliomas, such as chemotherapy and gene therapy, have remained largely unsuccessful. http://www.cancercompass.com/cancer-news/article/32372.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT About 100,500 new cases of cancer are caused by obesity every year, according to the most comprehensive attempt ever to estimate the cancers attributed to extra weight. The analysis, released today by the American Institute for Cancer Research, is based on updated cancer data and a report released earlier this year by a panel of experts. Among the types of cancer most strongly linked to excess body fat: http://www.cancercompass.com/cancer-news/article/32377.htm CancerCompass Fri, 06 Nov 2009 00:00:00 GMT Mollie Katzen's latest cookbook urges beginners to take on her challenge with easy recipes, such as this acorn squash entree. Use plain raw almonds, not roasted or salted, Katzen writes, and don't chop them too fine. You can cook the rice and bake the acorn squash at the same time. http://www.cancercompass.com/cancer-news/article/32356.htm CancerCompass Wed, 04 Nov 2009 00:00:00 GMT If you're watching your weight, soup can be deceptive. What could be more harmless for lunch or a light dinner? Not so fast. Depending on the recipe, some soups are full of cream and cheese, or sometimes worse, they start with a roux. In place of cream and butter, add flavor to soup with lots of vegetables, beef broth and dried and fresh herbs. http://www.cancercompass.com/cancer-news/article/32357.htm CancerCompass Wed, 04 Nov 2009 00:00:00 GMT Obesity, not the amount of radiation given, is the greatest factor in whether early-stage lung cancer patients develop chest wall pain after receiving stereotactic body radiation therapy to the chest wall, with obese patients being more than twice as likely to develop chronic pain compared to those who have less body weight, according to a first-of-its-kind study presented Tuesday, November 3, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). http://www.cancercompass.com/cancer-news/article/32343.htm CancerCompass Tue, 03 Nov 2009 00:00:00 GMT High-risk melanoma patients who are treated with radiation after surgery have a significantly lower risk of their cancer returning to the lymph nodes (19 percent), compared to those patients who do not have radiation therapy (31 percent), according to the first randomized study of its kind presented at the plenary session, November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). http://www.cancercompass.com/cancer-news/article/32347.htm CancerCompass Tue, 03 Nov 2009 00:00:00 GMT BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). http://www.cancercompass.com/cancer-news/article/32349.htm CancerCompass Tue, 03 Nov 2009 00:00:00 GMT Drink up, coffee lovers. Not only is coffee aromatic and delicious, it's good for you. Who says? None other than Harvard Medical School. Once considered questionable for your health, it turns out that the beloved beverage is actually healthful in moderation. That means a few cups a day. http://www.cancercompass.com/cancer-news/article/32341.htm CancerCompass Tue, 03 Nov 2009 00:00:00 GMT Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer. This Phase 3 trial was started based on the results from Phase 2 clinical trials evaluating Nexavar in patients with advanced thyroid cancer. http://www.cancercompass.com/cancer-news/article/32338.htm CancerCompass Fri, 30 Oct 2009 00:00:00 GMT The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005. Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. http://www.cancercompass.com/cancer-news/article/32339.htm CancerCompass Fri, 30 Oct 2009 00:00:00 GMT ImmunoCellular Therapeutics, Ltd. (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM). http://www.cancercompass.com/cancer-news/article/32318.htm CancerCompass Wed, 28 Oct 2009 00:00:00 GMT